Lilly's prescription for growth
Posted on August 15, 2004 at 5:45 PM
Filed under: Acquisitions | Corporate Strategy | Corporate Venture Capital | Cover Story | Joint Ventures and Alliances | July-Aug. 2004 | The Magazine
Tagged: alliances , biotech , Cialis , corporate strategy , David Thompson , Eli Lilly , joint venture , M&A , partnership , pharma , venture capital
Filed under: Acquisitions | Corporate Strategy | Corporate Venture Capital | Cover Story | Joint Ventures and Alliances | July-Aug. 2004 | The Magazine
Tagged: alliances , biotech , Cialis , corporate strategy , David Thompson , Eli Lilly , joint venture , M&A , partnership , pharma , venture capital
Eli Lilly and Co. spent $2.4 billion on life-science R&D last year, exploring everything from antisense technology to synthetic exendin-4. But the biggest experiment under way at the company isn't taking place in a lab or a clinic. And the results of that experiment - highly promising so far... Continue reading
















And the winners are...



